In an effort to promote education about Alzheimer’s disease and help local communities plan for this emerging public health crisis, Eli Lilly and Company has started an expansion of its “Community Conversations on Alzheimer’s” series with a panel discussion at the U.S. Conference of Mayors June 24-27 in Indianapolis.
Using slices of mouse brain tissue kept alive in a lab dish, scientists have identified the earliest molecular changes leading to Alzheimer’s disease. The findings, showing how early alterations in brain amyloid-β balance causes nerve connections called synapses to die, might allow scientist to target the mechanisms and develop therapies to…
vTv Therapeutics is recruiting patients for a large Phase 3 study, known as STEADFAST, assessing the drug azeliragon as a potential treatment for mild Alzheimer’s disease (AD). Study participants will be randomly assigned to take either a 5 mg pill containing azeliragon once a day, or a placebo (sugar pill), for 18 months, with…
Unbalanced, unhealthy zinc levels show in many diseases including Alzheimer’s disease, Parkinson’s disease, and pancreatic cancer. But lack of information about the molecular structure of zinc transporters hampers the discovery of new drugs to bring zinc to proper levels (homeostasis) with other important elements. Researchers at Michigan State University (MSU) have taken a new step toward the development of…
Two studies from the Washington University School of Medicine in St. Louis, Missouri, reveal new insights into amyloid-β — the plaque-forming protein scientists believe is at the root of Alzheimer’s disease. Both studies homed in on the removal of amyloid-β from the brain, a process thought to be defective in Alzheimer’s…
Scientists at the Buck Institute for Research on Aging recently demonstrated that memory loss for patients with early Alzheimer’s disease can be reversed — a feat the research team managed through a 36-point approach called metabolic enhancement for neurodegeneration. The multidisciplinary program is the first to show that cognitive decline and…
Muses Labs has partnered with the George Washington Center for Integrative Medicine (GWCIM) to offer Alzheimer’s disease (AD) patients in the Washington, D.C. area the MEND Protocol (Metabolic Enhancement for Neuro-Degeneration), a comprehensive adherence program supporting patients and their caregivers that helps to improve patient outcomes. The MEND…
Alzheimer’s Therapeutic Research Institute (ATRI) at the University of Southern California, and Janssen Research & Development will collaborate for a  Phase 2/3 clinical trial of Jansen’s BACE blocker intended to delay or even prevent Alzheimer’s symptoms. The BACE blocker is a drug that prevents the action of an enzyme involved in…
The U.S. Senate Appropriations Committee  has forwarded a draft bill that could deliver nearly $1.4 billion in federal funds to Alzheimer’s disease (AD) research in 2017. In all health concerns related to the proposed bi-partisan bill, lawmakers recommend $34 billion – a $2 billion increase over fiscal year 2016 – to the…
Recent research published in The Lancet Neurology demonstrates that blood vessel changes such as arteriosclerosis and atherosclerosis in the brain are linked to Alzheimer’s disease. The findings suggest that investigating the mechanisms behind how blood vessel disease might contribute to the development of dementia might enable the…
Get regular updates to your inbox.